share_log

Oppenheimer Reiterates Outperform on Moleculin Biotech, Maintains $5 Price Target

Benzinga ·  Mar 24, 2023 08:47

Oppenheimer analyst Jeff Jones reiterates Moleculin Biotech (NASDAQ:MBRX) with a Outperform and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment